Candriam Luxembourg S.C.A. Boosts Position in NewLink Genetics Corporation (NLNK)

Candriam Luxembourg S.C.A. grew its holdings in shares of NewLink Genetics Corporation (NASDAQ:NLNK) by 337.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 328,000 shares of the biotechnology company’s stock after buying an additional 253,000 shares during the quarter. Candriam Luxembourg S.C.A. owned approximately 1.12% of NewLink Genetics Corporation worth $3,339,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of NLNK. Columbus Circle Investors lifted its position in NewLink Genetics Corporation by 72.5% during the 2nd quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock worth $4,349,000 after buying an additional 248,724 shares in the last quarter. American Century Companies Inc. bought a new stake in NewLink Genetics Corporation during the 3rd quarter worth about $963,000. Quantitative Investment Management LLC bought a new stake in NewLink Genetics Corporation during the 2nd quarter worth about $635,000. PDT Partners LLC lifted its position in NewLink Genetics Corporation by 160.2% during the 2nd quarter. PDT Partners LLC now owns 115,795 shares of the biotechnology company’s stock worth $851,000 after buying an additional 71,295 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in NewLink Genetics Corporation by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock worth $23,134,000 after buying an additional 51,013 shares in the last quarter. 45.31% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.truebluetribune.com/2017/11/15/candriam-luxembourg-s-c-a-boosts-position-in-newlink-genetics-corporation-nlnk.html.

NewLink Genetics Corporation (NLNK) opened at $8.36 on Wednesday. NewLink Genetics Corporation has a 52 week low of $5.90 and a 52 week high of $25.17.

Several equities research analysts have commented on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a research report on Monday, September 25th. ValuEngine raised shares of NewLink Genetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Zacks Investment Research raised shares of NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research report on Saturday, July 29th. Stifel Nicolaus boosted their price target on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the stock a “buy” rating in a research report on Monday, September 11th. Finally, Jefferies Group LLC raised shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and boosted their price target for the stock from $7.00 to $26.00 in a research report on Friday, September 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. NewLink Genetics Corporation has a consensus rating of “Buy” and a consensus price target of $23.43.

In other news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the stock in a transaction dated Friday, October 6th. The shares were bought at an average cost of $10.25 per share, for a total transaction of $7,999,991.75. Following the purchase, the insider now directly owns 7,857,732 shares of the company’s stock, valued at $80,541,753. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 13.70% of the stock is owned by insiders.

NewLink Genetics Corporation Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Institutional Ownership by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply